07:00 , Oct 22, 2012 |  BC Week In Review  |  Company News

AiCuris, Merck deal

AiCuris granted Merck exclusive, worldwide rights to AiCuris' human cytomegalovirus (CMV) portfolio, including letermovir ( AIC246 ). AiCuris will receive €110 million ($142.5 million) up front and is eligible to receive up to €332.5 million...